Meeting
2018 ASCO Annual Meeting
Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.
Authors
Marina Chiara Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Marina Chiara Garassino , Delvys Rodriguez-Abreu , Shirish M. Gadgeel , Emilio Esteban González , Enriqueta Felip , Flavia De Angelis , Manuel Domine , Maximilian J. Hochmair , Steven Francis Powell , Susanna Y. Cheng , Helge Bischoff , Nir Peled , Martin Reck , Rina Hui , Edward B. Garon , Michael J. Boyer , Jing Yang , Thomas A. Burke , Maria Catherine Pietanza , Leena Gandhi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02578680
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9021)
DOI
10.1200/JCO.2018.36.15_suppl.9021
Abstract #
9021
Poster Bd #
344
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2020 ASCO Virtual Scientific Program
Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
First Author: Jhanelle Elaine Gray
Poster
2020 ASCO Virtual Scientific Program
Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).
First Author: Delvys Rodriguez-Abreu
Poster
2019 ASCO Annual Meeting
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
First Author: Shirish M. Gadgeel